Where can you network with more than 16,000 professionals in the field of rheumatology? Where you can hear about promising research and best practices from industry leaders? How can you find out about new treatments and technologies on the horizon? You guessed it—at the 2016 ACR/ARHP Annual Meeting, to be held Nov. 11–16. As if…
In June, state lawmakers in New York passed legislation on step therapy designed to help ensure patient access to the best and most appropriate care. Step therapy mandates that a patient with a specific condition receive prescribed drugs approved for that condition in the order that an insurance company determines it will cover as the…
NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…
Ethical issues that arise in the average rheumatology practice and in clinical research are often straightforward. The AMA Code of Medical Ethics and the Office Practice and Procedures Manual offer useful information.1 In research, the Protocol and Investigators Agreement spells out who you can enroll and how the trial must be conducted. But still—even when…
The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…
FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising…
Doctor-patient communication is critical for successfully treating rheumatoid arthritis. But a majority of RA patients report suboptimal shared decision making, sometimes due to language barriers, lack of time, limited health literacy and other factors. A recent pilot study sought to improve patient understanding and communication by employing an adapted medication guide and decision aid during clinical visits. Use of the tool, RA Choice, resulted in an increase in patient knowledge, and a majority of clinicians found it helpful…
CHICAGO—Celiac disease—the gluten-induced illness that can be seen alongside rheumatic diseases—has been seen much more commonly over the past 20 years than it was previously, but the illness can come with questions that are not always straightforward, an expert said at the ACR’s State-of-the-Art Clinical Symposium. The disease, in which the small intestine becomes inflamed…
A recent study from the U.K. calculated the incidence of comorbidity associated with systemic lupus erythematosus (SLE), specifically looking for cardiovascular disease, stroke, end-stage renal failure, cancer, osteoporosis and infection. Even after adjusting for age, sex and other variables, investigators found that people with SLE have an increased global burden of comorbidity compared with the general population. Additionally, the study found that men with SLE had higher rates of cardiovascular disease, stroke and cancer, while women with SLE had higher rates of infection and osteoporosis. Overall, younger people with SLE had the greatest relative risk compared with controls…
Take the challenge. B—No. Although the documentation states the patient arrived at the clinic at 8:15 a.m. and left the clinic at 10:55 a.m., it does not document the actual start and stop times of the infusion. According to CPT, when reporting codes for which infusion time is a factor, use the actual time over…